Vertex Pharmaceuticals Incorporated (VRTX) | Investment Case

1. Company Snapshot

1.a. Company Description

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis.The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial.

The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally.It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc.Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Show Full description

1.b. Last Insights on VRTX

Vertex Pharmaceuticals' recent performance has been driven by strong revenue growth, commercial diversification, and pipeline advancement. The company's Q4 2025 earnings report showed a 10% rise in revenue to $3.19 billion, with a focus on executing across the CF franchise and bringing CASGEVY to market. Analysts have a "Moderate Buy" consensus rating on the stock, with 17 buy ratings and 2 strong buy ratings (MarketBeat). Institutional investors have also shown confidence, with AXQ Capital LP, Graphene Investments SAS, and Galvin Gaustad & Stein LLC increasing their stakes.

1.c. Company Highlights

Last Price	474.27
Change Percentage	-2.42%
Open	478.95
Previous Close	486.03
Market Cap ( Millions)	120465
Volume	1055517
Year High	519.68
Year Low	362.5
M A 50	466.32
M A 200	436.5

FCF Yield	2.65%
Dividend Yield	0.00%
ROE	22.70%
Debt / Equity	20.80%
Net Debt / EBIDTA	-24.96%
Price To Book	6.45
Price Earnings Ratio	30.46
Price To FCF	37.72
Price To sales	10.01
EV / EBITDA	24.69

2. Vertex Pharmaceuticals' Q4 2025 Earnings: Strong Performance and Growth Prospects

Vertex Pharmaceuticals reported a strong financial performance in Q4 2025, with total revenue reaching $3,200,000,000, a 10% increase compared to Q4 2024. For the full year, total revenue was $12,000,000,000, an increase of 9% versus 2024. The company's cystic fibrosis therapies remain the foundation of its revenue and cash flow, with full-year 2025 growth of 7% globally. The EPS came out at $5.03, slightly below estimates of $5.11. For 2026, the company expects total company revenue to be in the range of $12,950,000,000 to $13,100,000,000, representing 8% to 9% growth versus the prior year.

Publication Date: Feb -13

📋 Highlights

Revenue Growth Drivers

The company's CF franchise continues to drive revenue growth, with 11% year-over-year growth in the U.S. largely due to pediatric uptake, ongoing strength in TRIKAFTA and ELEFTREC, higher realized net prices, and a modest benefit from channel inventory in the fourth quarter. The company is also making progress in expanding its renal pipeline, with Povatacept (Povi) being the most advanced asset. Povi is a dual BAFF/APRIL inhibitor for IgA nephropathy (IgAN), a progressive kidney disease affecting 330,000 people in the U.S. and Europe.

Renal Pipeline Progress

Vertex is advancing its renal pipeline, with Povi being developed for IgAN and membranous nephropathy. The company has received Breakthrough Therapy designation from the FDA for Povi in IgAN and Fast Track and EMA PRIME designations for Povi in membranous nephropathy. As Reshma Kewalramani stated, "We are excited to continue to drive a transformation in the management of... kidney disease areas, including intense focus on the patient, an unrelenting commitment to serial innovation in R&D..."

Valuation Metrics

Using the provided valuation metrics, Vertex Pharmaceuticals has a P/E Ratio of 32.34, P/B Ratio of 6.86, and P/S Ratio of 10.17. The EV/EBITDA ratio is 24.92. These metrics suggest that the company is trading at a premium, with the P/E Ratio indicating that the company's growth prospects are already priced in to some extent. Analysts estimate next year's revenue growth at 10.0%, which may justify the current valuation.

3. NewsRoom

Vertex Pharmaceuticals Incorporated (VRTX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar -03

Source: seekingalpha.com

111 Capital Invests $1.71 Million in Vertex Pharmaceuticals Incorporated $VRTX

Mar -02

Source: defenseworld.net

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Mar -02

Source: defenseworld.net

10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)

Feb -28

Source: seekingalpha.com

Duncan Mckechnie Sells 4,910 Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) Stock

Feb -28

Source: defenseworld.net

2 Top Healthcare Stocks to Buy in February

Feb -26

Source: fool.com

The Ultimate Biotech Stock to Buy With $500 Right Now

Feb -24

Source: fool.com

Market Today: Tariffs, AI Jitters; LLY, MRK, WBD in Focus

Feb -23

Source: gurufocus.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (12.40%)

6. Segments

Pharmaceuticals

Expected Growth: 12.4%

Vertex Pharmaceuticals' growth drivers include its dominance in cystic fibrosis treatment and increasing demand for oncology medications

7. Detailed Products

TRIKAFTA

A prescription medicine used for the treatment of cystic fibrosis in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

SYMDEKO

A prescription medicine used for the treatment of cystic fibrosis in patients aged 12 years and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

ORKAMBI

A prescription medicine used for the treatment of cystic fibrosis in patients aged 2 years and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

KALYDECO

A prescription medicine used for the treatment of cystic fibrosis in patients aged 4 months and older who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R.

INCIVEK

A prescription medicine used for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection in adults with compensated liver disease, including cirrhosis.

8. Vertex Pharmaceuticals Incorporated's Porter Forces

Forces Ranking

Threat Of Substitutes

Vertex Pharmaceuticals Incorporated has a moderate threat of substitutes due to the presence of alternative treatments for cystic fibrosis and other diseases. However, the company's strong pipeline and innovative products reduce the threat of substitutes.

Bargaining Power Of Customers

Vertex Pharmaceuticals Incorporated has a low bargaining power of customers due to the lack of negotiating power of individual patients and the high demand for its products.

Bargaining Power Of Suppliers

Vertex Pharmaceuticals Incorporated has a low bargaining power of suppliers due to the company's strong relationships with its suppliers and the lack of dependence on a single supplier.

Threat Of New Entrants

Vertex Pharmaceuticals Incorporated has a low threat of new entrants due to the high barriers to entry in the pharmaceutical industry, including the need for significant research and development investments and regulatory approvals.

Intensity Of Rivalry

Vertex Pharmaceuticals Incorporated operates in a highly competitive industry with several established players, leading to a high intensity of rivalry. The company must continuously innovate and invest in research and development to maintain its market position.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	4.40%
Debt Cost	5.87%
Equity Weight	95.60%
Equity Cost	5.87%
WACC	5.87%
Leverage	4.60%

11. Quality Control: Vertex Pharmaceuticals Incorporated passed 8 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

AbbVie

A-Score: 6.7/10

Value: 3.1

Growth: 4.7

Quality: 7.2

Yield: 7.0

Momentum: 9.5

Volatility: 9.0

1-Year Total Return ->

McKesson

A-Score: 6.1/10

Value: 5.4

Growth: 8.3

Quality: 4.5

Yield: 0.0

Momentum: 9.5

Volatility: 8.7

1-Year Total Return ->

Innoviva

A-Score: 5.5/10

Value: 4.7

Growth: 5.4

Quality: 6.6

Yield: 0.0

Momentum: 8.0

Volatility: 8.0

1-Year Total Return ->

Regeneron Pharmaceuticals

A-Score: 4.9/10

Value: 4.0

Growth: 6.4

Quality: 8.8

Yield: 0.0

Momentum: 4.0

Volatility: 6.3

1-Year Total Return ->

Vertex Pharmaceuticals

A-Score: 4.0/10

Value: 1.5

Growth: 3.8

Quality: 8.9

Yield: 0.0

Momentum: 3.5

Volatility: 6.7

1-Year Total Return ->

Moderna

A-Score: 3.0/10

Value: 7.7

Growth: 2.3

Quality: 4.8

Yield: 0.0

Momentum: 1.0

Volatility: 2.3

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

6.24%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

5.87%

Vertex Pharmaceuticals Incorporated - US92532F1003

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on VRTX

1.c. Company Highlights

Better Quality

Less Volatile

Expensive

Earnings Beats

Revenues Beats

Earnings Miss

Higher Growth

Strong Momentum

Revenues Miss

Stable Momentum

Fairly Valued

Average Quality

Average Yield

Average Growth

2. Vertex Pharmaceuticals' Q4 2025 Earnings: Strong Performance and Growth Prospects

Revenue Growth Drivers

Renal Pipeline Progress

Valuation Metrics

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (12.40%)

6. Segments

Pharmaceuticals

Expected Growth: 12.4%

7. Detailed Products

TRIKAFTA

SYMDEKO

ORKAMBI

KALYDECO

INCIVEK

8. Vertex Pharmaceuticals Incorporated's Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Vertex Pharmaceuticals Incorporated passed 8 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

474.27$

Current Price

474.27$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA